Genomics in Assessing Melanoma Prognosis

Area of Science:

• Genomic medicine
• Dermatology
• Cancer research

Background:

• Melanoma prognosis traditionally relies on staging, but genomic advancements offer refined risk assessment.
• Gene expression profiling (GEP) tests identify genetic alterations impacting melanoma progression and treatment.
• GEP tests like 31-GEP, 11-GEP, and 8-GEP + CP stratify patients by metastasis risk.

Purpose of the Study:

• To evaluate the role of GEP tests in refining melanoma prognosis and clinical decision-making.
• To assess the impact of GEP on guiding treatment strategies and patient surveillance.
• To review the prognostic accuracy and challenges associated with GEP adoption in melanoma.

Main Methods:

• Analysis of genomic data and gene expression profiling results.
• Correlation of GEP findings with patient outcomes, including recurrence and survival.
• Review of clinical utility in sentinel lymph node biopsy, surveillance, and adjuvant therapy decisions.

Main Results:

• GEP tests demonstrate significant prognostic accuracy, refining traditional melanoma staging.
• GEP stratification effectively identifies patients at high risk for recurrence and metastasis.
• Clinical decision-making for sentinel lymph node biopsy, surveillance, and adjuvant therapy is enhanced by GEP results.

Conclusions:

• GEP tests are valuable tools for personalizing melanoma management and improving prognostic accuracy.
• Integrating genomic data with traditional staging offers a path toward more precise patient care.
• Addressing challenges such as cost and validation is crucial for broader GEP test adoption in clinical practice.